Creative Planning Boosts Holdings in Humana Inc. $HUM

Creative Planning raised its holdings in Humana Inc. (NYSE:HUM) by 20.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,282 shares of the insurance provider’s stock after purchasing an additional 5,404 shares during the quarter. Creative Planning’s holdings in Humana were worth $7,648,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cary Street Partners Investment Advisory LLC grew its stake in Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after acquiring an additional 46 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of Humana during the 1st quarter valued at about $37,000. CVA Family Office LLC increased its position in Humana by 63.4% during the second quarter. CVA Family Office LLC now owns 219 shares of the insurance provider’s stock worth $54,000 after purchasing an additional 85 shares during the last quarter. Ransom Advisory Ltd acquired a new stake in Humana during the first quarter worth about $66,000. Finally, Transamerica Financial Advisors LLC lifted its position in Humana by 1,027.6% during the first quarter. Transamerica Financial Advisors LLC now owns 327 shares of the insurance provider’s stock valued at $87,000 after buying an additional 298 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Trading Down 2.2%

Shares of NYSE:HUM opened at $228.94 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The stock has a market capitalization of $27.53 billion, a price-to-earnings ratio of 17.57, a PEG ratio of 1.71 and a beta of 0.42. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $315.35. The company has a 50 day moving average price of $267.88 and a 200 day moving average price of $257.49.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.29. The company had revenue of $32.65 billion for the quarter, compared to analysts’ expectations of $31.99 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.16 earnings per share. On average, research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a $0.885 dividend. The ex-dividend date is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.5%. Humana’s dividend payout ratio (DPR) is 33.18%.

Analysts Set New Price Targets

HUM has been the topic of several recent research reports. Mizuho boosted their price target on Humana from $300.00 to $345.00 and gave the stock an “outperform” rating in a research report on Thursday, October 9th. Wells Fargo & Company lifted their price target on Humana from $344.00 to $347.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 7th. Evercore ISI assumed coverage on shares of Humana in a report on Monday, September 22nd. They issued an “in-line” rating and a $295.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Humana in a report on Friday, October 3rd. Finally, Royal Bank Of Canada increased their price objective on shares of Humana from $283.00 to $322.00 and gave the stock an “outperform” rating in a report on Thursday, August 21st. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $298.39.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.